Publications

Selected Publications

    1. Doria A, Wojcik J, Xu R, Gervino EV, Hauser TH, Johnston MT, Nolan D, Hu FB, Warram JH. Interaction between poor glycemic control and 9p21 locus on risk of coronary artery disease in type 2 diabetes. JAMA. 2008;300(20):2389-97. PMID:19033589
    2. Borowiec M, Liew CW, Thompson R, Boonyasrisawat W, Hu J, Mlynarski WM, El Khattabi I, Kim SH, Marselli L, Rich SS, Krolewski AS, Bonner-Weir S, Sharma A, Sale M, Mychaleckyj JC, Kulkarni RN, Doria A. Mutations at the BLK locus linked to maturity onset diabetes of the young and beta-cell dysfunction. Proc Natl Acad Sci U S A. 2009;106(34):14460-5. PMID:19667185
    3. Qi L, Parast L, Cai T, Powers C, Gervino EV, Hauser TH, Hu FB, Doria A. Genetic susceptibility to coronary heart disease in type 2 diabetes: three independent studies. J Am Coll Cardiol. 2011;58(25):2675-82. PMID: 22152955
    4. Qi L, Qi Q, Prudente S, Mendonca C, Andreozzi F, Di Pietro N, Sturma M, Novelli V, Mannino GC, Formoso G, Gervino EV, Hauser TH, Muehlschlegel JD, Niewczas MA, Krolewski AS, Biolo G, Pandolfi A, Rimm E, Sesti G, Trischitta V, Hu FB, Doria A. Association between a genetic variant related to glutamic acid metabolism and coronary heart disease in type 2 diabetes. JAMA. 2013;310(8):821-828. PMID: 23982368
    5. Prudente S, Shah H, Bailetti D, Pezzolesi M, Buranasupkajorn P, Mercuri L, Mendonca C, De Cosmo S, Niewczas M, Trischitta V, Doria A. Genetic variant at the GLUL locus predicts all-cause mortality in patients with type 2 diabetes. Diabetes. 2015; 64(7):2658-63. PMID:25677913
    6. Prudente S, Jungtrakoon P, Marucci A, Ludovico O, Buranasupkajorn P, Mazza T, Hastings T, Milano T, Morini E, Mercuri L, Bailetti D, Mendonca C, Alberico F, Basile G, Romani M, Miccinilli E, Pizzuti A, Carella M, Barbetti F, Pascarella S, Marchetti P, Trischitta V, Di Paola R, Doria A. Loss-of-function mutations in the APPL1 gene in familial diabetes mellitus. Am J Hum Genet. 2015; 97(1):177-85. PMID:26073777
    7. Shah HS, Gao H, Morieri ML, Skupien J, Marvel S, Paré G, Mannino GC, Buranasupkajorn P, Mendonca C, Hastings T, Marcovina SM, Sigal RJ, Gerstein HC, Wagner MJ, Motsinger-Reif AA, Buse JB, Kraft P, Mychaleckyj JC, Doria A. Genetic predictors of cardiovascular mortality during intensive glycemic control in type 2 diabetes: findings from the ACCORD clinical trial. Diabetes Care. 2016; 39(11):1915-24. PMID: 27527847
    8. Morieri ML, Shah HS, Doria A. Comment on: Variants in ANGPTL4 and the Risk of Coronary Artery Disease. N Engl J Med. 2016; 375(23):2304-5
    9. Shah HS, Morieri ML, Marcovina SM, Sigal RJ, Gerstein HC, Wagner MJ, Motsinger-Reif AA, Buse JB, Kraft P, Mychaleckyj JC, Doria A. Modulation of GLP-1 levels by a genetic variant that regulates the cardiovascular effects of intensive glycemic control in ACCORD. Diabetes Care 2018;41(2):348-355. PMID:29183908
    10. Morieri ML, Gao H, Pigeyre M, Shah HS, Sjaarda J, Mendonca C, Hastings T, Buranasupkajorn P, Motsinger-Reif AA, Rotroff DM, Sigal RJ, Marcovina SM, Kraft P, Buse JB, Wagner MJ, Gerstein HC, Mychaleckyj JC, Parè G, Doria A. Genetic tools for coronary risk assessment in type 2 diabetes: a cohort study from the ACCORD clinical trial. Diabetes Care 2018; 41(11):2404-2413. PMID: 30262460
    11. Tang Y, Lenzini PA, Pop Busui R, Ray PR, Campbell H, Perkins BA, Callaghan B, Wagner MJ, Motsinger-Reif AA, Buse JB,  Price TJ, Mychaleckyj JC, Cresci S,  Shah H, Doria A. A genetic locus on chromosome 2q24 predicting peripheral neuropathy risk in type 2 diabetes: results from the ACCORD and BARI 2D studies. Diabetes 2019;68(8):1649-1662. PMID:31127053
    12. Afkarian M, Polsky S, Parsa A, Aronson R, Caramori ML, Cherney DZ, Crandall JP, de Boer IH, Elliott TG, Galecki AT, Goldfine AB, Haw JS, Hirsch IB, Karger AB, Lingvay I, Maahs DM, McGill JB, Molitch ME, Perkins BA, Pop-Busui R, Pragnell M, Rosas SE, Rossing P, Senior P, Sigal RJ, Spino C, Tuttle KR, Umpierrez GE, Wallia A, Weinstock RS, Wu CY, Mauer M, Doria A, PERL Study Group. Preventing Early Renal Loss (PERL) in Diabetes Study, a randomized double blinded trial of allopurinol: rationale, design, and baseline data. Diabetes Care 2019;42(8):1454-1463. PMID:31186299
    13. Morieri ML, Shah HS, Sjaarda J, Lenzini PA, Campbell H, Motsinger-Reif AA, Gao H, Lovato L, Prudente S, Pandolfi A, Pezzolesi MG, Sigal RJ, Paré G, Marcovina SM, Rotroff DM, Patorno E, Mercuri L, Trischitta V, Chew EY, Kraft P, Buse JB, Wagner MJ, Cresci S, Gerstein HC, Ginsberg HN, Mychaleckyj JC, Doria A. A PPARA polymorphism influences the cardiovascular benefit of fenofibrate in type 2 diabetes: findings from ACCORD lipid. Diabetes 2020;69(4):771-783. PMID:31974142